Copyright: ©Author(s) 2026.
World J Stem Cells. Aug 26, 2026; 18(8): 122836
Published online Aug 26, 2026. doi: 10.4252/wjsc.122836
Published online Aug 26, 2026. doi: 10.4252/wjsc.122836
Table 1 Baseline clinical and laboratory characteristics of patients stratified by early vs slow engraftment group after autologous hematopoietic stem cell transplantation, n (%)
| Variable | Early engraftment group | Slow engraftment group | P value |
| Baseline characteristics | |||
| Age (years), median (IQR, Q1-Q3) | 50 (38-56) | 55 (47.5-61.5) | 0.0011,a |
| Sex | 0.3922 | ||
| Male | 43 (62.3) | 54 (55.7) | |
| Female | 26 (37.7) | 43 (44.3) | |
| BM involvement at diagnosis | 0.7742 | ||
| Yes | 11 (16.4) | 16 (18.2) | |
| No | 56 (83.6) | 72 (81.8) | |
| Ann Arbor stage | 0.1332 | ||
| IV | 33 (55.9) | 58 (70.7) | |
| Non-IV | 26 (44.1) | 24 (29.3) | |
| Risk stratification | 0.3842 | ||
| High risk | 15 (30.0) | 26 (37.7) | |
| Non-high risk | 35 (70.0) | 43 (62.3) | |
| LDH at diagnosis (U/L), median (IQR, Q1-Q3) | 228 (175.5-393.3) | 292 (204-546) | 0.0391,a |
| β2-MG at diagnosis (mg/L), median (IQR, Q1-Q3) | 2.58 (1.9-4.2) | 3.215 (2.3-4.4725) | 0.1141 |
| HB at diagnosis (g/L), median (IQR, Q1-Q3) | 129 (111.5-136) | 119 (102-133.75) | 0.0431,a |
| WBC at diagnosis (× 109/L), median (IQR, Q1-Q3) | 6.29 (4.83-8.03) | 6.24 (4.72-7.8875) | 0.5971 |
| PLT at diagnosis (× 109/L), median (IQR, Q1-Q3) | 228 (172.5-293) | 239.5 (155-307.75) | 0.8311 |
| Transplant-related indicators | |||
| CD34+ cells (× 106/kg), median (IQR, Q1-Q3) | 5.27 (3.93-8.645) | 3.59 (2.64-5.54) | < 0.0011,a |
| Mononuclear cells (× 108/kg), median (IQR, Q1-Q3) | 5.15 (3.44-7.055) | 5.01 (3.7-7.64) | 0.7291 |
| Stem cell storage time (days), median (IQR, Q1-Q3) | 46 (33-70) | 50 (30-72.5) | 0.9261 |
| Pretransplant indicators | |||
| Pretransplant remission status | 0.1742 | ||
| CR | 47 (68.1) | 56 (57.7) | |
| NR | 22 (31.9) | 41 (42.3) | |
| Change in BMI (kg/m2), median (IQR, Q1-Q3) | 0 (-0.535 to 0.335) | -0.35 (-1.7525 to 0.065) | 0.0251,a |
| Pretransplant nutritional score, median (IQR, Q1-Q3) | 2 (2-2) | 2 (2-2) | 0.1351 |
| Pretransplant albumin (g/L), mean ± SD | 27.08 ± 5.38 | 26.10 ± 5.55 | 0.2573 |
| Pretransplant prealbumin (mg/L), median (IQR, Q1-Q3) | 236 (203-265.32) | 236 (214-267) | 0.661 |
| Pretransplant globulin (g/L), median (IQR, Q1-Q3) | 39.8 (37.6-44.2) | 40.92 (37-44.2) | 0.7321 |
| Pretransplant LDH (U/L), median (IQR, Q1-Q3) | 203.5 (182-269.25) | 221 (181-282.5) | 0.5241 |
| Pretransplant β2-MG (mg/L), median (IQR, Q1-Q3) | 2.465 (1.9-3) | 2.715 (2.2125-3.3375) | 0.0161,a |
| Pretransplant HB (g/L), mean ± SD | 105.9 ± 18.7 | 102.5 ± 17.5 | 0.2323 |
| Pretransplant WBC (× 109/L), median (IQR, Q1-Q3) | 3.96 (2.9-5.795) | 3.83 (2.855-5.9275) | 0.8841 |
| Pretransplant PLT (× 109/L), median (IQR, Q1-Q3) | 199 (148-253) | 183 (131-215.75) | 0.0721 |
- Citation: Quan X, Zhang HB, Ran LR, Luo ZM, Zhang N, Hu X, Deng JC, Liu Y, Lou SF. Pretransplant T-cell immune imbalance predicts slow engraftment after autologous hematopoietic stem cell transplantation in lymphoma. World J Stem Cells 2026; 18(8): 122836
- URL: https://www.wjgnet.com/1948-0210/full/v18/i8/122836.htm
- DOI: https://dx.doi.org/10.4252/wjsc.122836